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Background: Ultrasound is an alternative to Magnetic Resonance Enterography, and has 56 
the potential to significantly reduce waiting times, expedite clinical decision making and 57 
improve patient experience. Point of care ultrasound is an advantage of the US imaging 58 
modality, where same day scanning, interpretation and treatment decisions can be made. 59 
 60 
Aim: To systematically scope the literature on point of care ultrasound use in small bowel 61 
Crohn’s disease, generating a comprehensive list of factors relating to the current 62 
understanding of clinical utility of this imaging modality. 63 
 64 
Methods: Searches included: MEDLINE, EMBASE, Cochrane Library, CINAHL, PsycINFO, 65 
clinicaltrial.gov,‘TRIP’ and Epistemonikos. Reference lists of included studies were hand 66 
searched. Search terms were searched for as both keywords and subject headings (MeSH) 67 
as appropriate. Searches were performed with the ‘suggested search terms’ and ‘explode’ 68 
selection, and restricted to ‘human’, ‘adult’ and ‘English language’ publications. No date 69 
limits were applied to be as inclusive as possible. Two investigators conducted abstract and 70 
full text review. No formal quality appraisal process was undertaken; however, quality of 71 
sources was considered when reporting findings. A narrative synthesis was conducted.  72 
 73 
Results: The review included 42 sources from the UK, Europe, Japan, Canada and the 74 
USA. SBUS has been shown to be as accurate in detecting presence of SBCD, is quicker, 75 
safer and more acceptable to patients,compared to magnetic resonance enterography. small 76 
bowel ultrasound is used widely in central Europe and Canada but has not been embraced 77 
in the UK. Further research considering economic evaluation, clinical decision making and 78 
exploration of perceived barriers to future implementation of small bowel ultrasounds is 79 
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Key points:  86 
 87 
1. What is known: SBUS has been shown have a relatively comparable accuracy to 88 
MRE in detecting presence of SBCD. SBUS, and POCUS, are used widely in central 89 
Europe, Canada and some parts of the USA, but has not been embraced in the UK 90 
and other parts of the world. 91 
2. What this study adds: This study consolidates and comprehensively presents what 92 
is known regarding the clinical utility of small bowel ultrasounds and point of care 93 
ultrasound for use in Crohn’s Disease. This study gives insight into the future 94 
directions of research in this field. 95 
3. Future implications of this work: this study is the first step in a programme of work 96 
to investigate barriers and enablers to implementation of a small bowel ultrasound, 97 
point of care, service for Crohn’s Disease in the NHS. Through this work we have 98 
been able to better direct our research to investigate stakeholder perceptions of 99 
barriers to implementation, clinical decision-making behaviours and cost 100 
effectiveness studies.  101 
 102 
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The UK prevalence of Crohn’s Disease (CD) is one of the highest world-wide.1 The mean 138 
cost per patient-year during follow-up has been reported as €3542 (median €717 [214–139 
3512]) for patients with CD, with an overall annual cost to the National Health Service (NHS) 140 
of up to £470 million.2   141 
 142 
Assessing treatment response with more objective measures and a wider array of biological 143 
therapies has significantly increased the projected IBD healthcare burden for the next 144 
decade. 3,4 To ensure cost-effective IBD practice, complex and expensive pharmacological 145 
interventions should be targeted at patients most likely to benefit.5 146 
 147 
Cross sectional imaging is used to diagnose and monitor disease activity in small bowel CD 148 
(SBCD).6 Magnetic Resonance Enterography (MRE),with oral preparation and intravenous 149 
contrast is a standard of care modality in the UK for assessment and monitoring of SBCD.6 150 
However, waiting times for an NHS MRE may be up to 4 weeks or in some instances longer, 151 
with reporting is then undertaken at a later date. Additionally, the use of gadolinium as 152 
contrast agent has a risk of allergy, is expensive and has been implicated with long-term 153 
brain deposition in exposed patients.7 The European Crohn’s and Colitis Organisation 154 
[ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ECCO- 155 
ESGAR] guidelines have already negated some of the risks posed by the use of gadolinium, 156 
by stating that gadolinium should be used on a case by case basis.8 Some centres are 157 
moving away from its use and have shown no significant decrease in accuracy.9 However, 158 
there is still a clinical need to find quicker, more tolerable and cheaper alternatives for 159 
monitoring patients with IBD. 160 
 161 
Abdominal ultrasound (US) is an alternative to MRE, with the potential to reduce waiting 162 
times, speed up clinical decision-making and improve patient experiences and outcomes.10 163 
Point of Care (Abdominal) US (POCUS) is an advantage of the US imaging modality, where 164 
same day scanning and interpretation can be undertaken.  165 
 166 
This review is undertaken as the first step in investigating the use of POCUS for assessment 167 
of disease activity in SBCD. Due to the vastness of the existing evidence and the objective 168 
of this review,  it was decided that a scoping review, rather than a systematic literature 169 
review, was more appropriate.11 The objective was to systematically scope the literature on 170 
POCUS use in SBCD, identify specific characteristics and expand the current understanding 171 
of the clinical utility of POCUS for patients with SBCD.  172 
 173 
Multidimensional model of clinical utility 174 
Clinical utility can be described as a multi-dimensional judgement about the usefulness, 175 
benefits, and drawbacks of an intervention. The model of dimensions of clinical utility 176 
presented by Smart12 (Figure 1) provides a frame work for assessing the clinical utility of a 177 
new technology or technique, asking whether the innovation is appropriate, accessible, 178 
practicable, and acceptable for the purposes of the task intended. In this scoping review, 179 
factors were identified and grouped into themes in relation to the factors of clinical utility. 180 
 181 
Methods 182 
Preliminary searches of MEDLINE, Cochrane Database of Systematic Reviews and JBI 183 
Evidence Synthesis were conducted, no current systematic reviews or scoping reviews on 184 
the same topic were identified. Methods for this study were developed based on established 185 
scoping review methodology. 13,14 The research question was: “What evidence is currently 186 
available on the clinical utility of POCUS for the diagnosis and management of SBCD?”. 187 
 188 
Inclusion criteria: 189 
Searches of electronic databases of published literature included: MEDLINE, EMBASE, the 190 
Cochrane Library, Cumulative Index to Nursing and Allied Health Literature (CINAHL) and 191 
PsycINFO. Searches were also conducted of clinicaltrial.gov for current clinical trials, ‘TRIP’ 192 
and Epistemonikos. Reference lists of included studies, grey literature and non-indexed 193 
sources were hand searched to identify additional sources of relevance.  194 
 195 
Search terms were searched as keywords in title and/or abstract and subject headings 196 
(MeSH) as appropriate. Search terms (Table 1) were determined through consideration of 197 
previously reviewed literature and preliminary searches of Google Scholar. The Boolean 198 
operator ‘OR’ was used within each facet to maximise searches, with the operator ‘AND’ 199 
used between facets to combine terms, truncation of terms was used to be as inclusive as 200 
possible. Searches were performed with ‘suggested search terms’ and ‘explode’ selection, 201 
included any type of study design, and restricted to ‘human’, ‘adult’ and ‘English language’ 202 
publications. No date limits were applied to be as inclusive as possible. 203 
Table 1: Key search terms 
Crohn’s Disease (MeSH) Small Bowel Ultrasound (MeSH) 
Crohn’s Disease ileal Ultrasound 
Crohn’s Ileum US 
CD Ileitis  Sonography 
Crohn*  Echography 




Two investigators (SJR and GWM) independently screened the title and abstract of all 205 
retrieved citations for inclusion against inclusion criteria. Each author reviewed each title and 206 
abstract, if both agreed to include the full text for review it was included, if both chose to 207 
exclude it was excluded. There were no disagreements which led to the need for a third 208 
author deliberation.  No formal quality appraisal process was undertaken; however, quality of 209 
sources was considered when reporting findings.  210 
 211 
The two investigators (SJR and GWM) then each independently assessed all full-text articles 212 
to determine if they met inclusion criteria. There were no disagreements about study 213 
eligibility at the full-text review stage that required discussion with a third investigator. 214 
Reasons for exclusion of full text sources were recorded and reported in the PRISMA15 flow 215 
diagram (Figure 2). A narrative synthesis was conducted to explore relationships within and 216 




The review included 42 sources (table 2). A common view across 24 of the included sources 221 
was that US is non-invasive test that is acceptable to and well tolerated by patients, is safe 222 
and is inexpensive.8,10,16–37  223 
 224 
Only four sources directly mention the use of POCUS.10,30,36,38 the remainder discuss the use 225 
of small bowel ultrasound (SBUS). For the purposes of this review, we consider the use of 226 
SBUS without contrast agents, minimal or no bowel preparation and not the use of 227 
specialised tests such as doppler or elastography scanning.  228 
 229 
In central Europe and Canada SBUS is widely used, often performed by gastroenterologists. 230 
This allows gastroenterologists to have a whole view of patient management, reducing 231 
waiting times for clinical decision making.34,36 232 
 233 
The METRIC study showed that both SBUS and MRE had a diagnostic accuracy above 90% 234 
for detecting SBCD. Sensitivity of SBUS for small bowel disease presence and extent were 235 
92% and 70% respectively.39 Sensitivity and specificity were significantly greater for MRE, 236 
with a 10% and 14% difference for extent and a 5% and 12% difference for presence.39 It 237 
was also found that there was substantial sonographic agreement for the presence of 238 
SBCD, both in newly diagnosed and relapsed disease. 40 Agreement for SBCD extent was 239 
inferior to that of presence alone; this is in contrast to previous work by Parente et al41, who 240 
reported near perfect agreement for segmental localisation.  241 
 242 
The most prominent parameter for detection of inflammation throughout the reviewed 243 
sources was bowel wall thickness (BWT), which correlates well with clinical disease activity 244 
markers.8,10,17–22,24,25,27–29,32,34,35,37,38,42–46 The most common cut off value was BWT exceeding 245 
3mm being considered pathological and a BWT of 2mm or less considered normal.31,32,42  246 
 247 
A number of SBUS scores have been developed, most lack validation, were developed from 248 
small sample sizes or are limited to quantification of ‘damage’ or the risk of surgery.25,47 249 
Novak et al25 have developed a promising, simple US score for identifying CD activity 250 
comparing BWT to endoscopic activity, however the results reported have not yet been 251 
externally validated.25 252 
 253 
Fraquelli et al34 notes that the use of SBUS in different clinical settings may impact on the 254 
utility of SBUS. In specialist centres where the pre-test probability of IBD is elevated, US 255 
would be used to ‘rule in’ the disease. Alternatively, in primary care SBUS would be a useful 256 
tool to ‘rule out’ the disease.48 257 
 258 
Paredes et al49 used SBUS for assessing changes induced with an anti-tumour necrosing 259 
factor (TNF) therapy in CD. The study reported a significant reduction in BWT in patients 260 
receiving anti-TNF therapy, however, ‘resolution’ of inflammation visible on SBUS was only 261 
achieved in 29% of subjects.34 Results from Ripolles et al 45showed that SBUS may be able 262 
to predict the 1 year response to anti-TNF therapy after 12 weeks of treatment with 85%  263 
(22/26) of patients showing a sonographic response at 12 and 52 weeks. Moreover, in the 264 
majority of patients (96%), clinical and biological response corresponded to sonographic 265 
response. Multiple authors suggest that SBUS may have a role in supporting MRE as a 266 
useful examination for monitoring the response to treatment in CD patients.23,29,34,38,50 267 
 268 
The METRIC39 study found no major difference between MRE and SBUS on therapeutic 269 
decision-making. Both tests agreed with a final therapeutic decision based on all tests in > 270 
75% of cases. Very little further investigation into the impact of the use of SBUS on the 271 
clinical decision-making behaviours of clinicians has been undertaken, nor exploration of the 272 
confidence of clinical decisions made using each imaging modality.  273 
 274 
Multiple sources refer to SBUS being inexpensive, however there is little empirical evidence 275 
within the included sources to support this claim.20–23,26,39,51 The METRIC39 study presents 276 
data on a cost-utility analysis of MRE vs SBUS indicating a trend towards SBUS over MRE. 277 
However, given the small non-significant differences in costs and QALYs between the two 278 
options, it was not possible to endorse US or MRE on cost-effectiveness grounds. 279 
 280 
The benefits of POCUS being performed by a member of the clinical IBD team include 281 
increased capacity for real time interpretation of findings, expediting decisions concerning 282 
disease management and strengthening the rapport between Health care professionals 283 
(HCPs) and patients.35,36,38 Many centres have standalone IBD US lists. These lists may be 284 
advantageous in expanding capacity to perform SBUS, particularly in centres where 285 
gastroenterologists are not trained in SBUS. This may also maximise healthcare resource 286 
allocation via predictable patient bookings.36  287 
 288 
Over the last few years, outside of the UK, the widespread availability of US technology and 289 
the increasing expertise of practitioners has boosted the uptake and role of US in assessing 290 
patients with IBD.31,34,39,43 Throughout the included sources results reported were from SBUS 291 
being performed by individuals with extensive experiences of SBUS. 16,17,19–21,26,28–30,37,44,45,48 292 
For example, Taylor et al 39 reports that the team involved in the METRIC study had an 293 
average of 8 years (4-11) experience of interpreting US. Despite SBUS typically being 294 
performed using standard devices and techniques, the uptake is not widespread or 295 
universal. Multiple authors have speculated this is due to lack of training availability and the 296 
substantial training and experience requirements of those preforming the test.34,52 However, 297 
interobserver agreement between sonographers with variable experience in SBUS has been 298 
reported in preliminary studies showing satisfactory results.10,16,17,34,36,37,40,42,48 With 299 
appropriate training, transabdominal US can be performed by specialist gastroenterologists 300 
in clinic as part of routine care.30 Gastroenterologist-performed SBUS is yet to establish 301 
universal acceptance.53 The benefit of SBUS being performed within a radiology department 302 
by a dedicated sonographer or radiologist is the potential for increased diagnostic accuracy 303 
in detecting pathology.36  304 
 305 
SBUS and MRE are the most preferred imaging modalities by patients with CD.39 SBUS is 306 
well tolerated by patients with IBD.8,26 MRE recovery time has been shown to be significantly 307 
longer than US, with 15 participants out of 149 (10%) reporting immediate recovery following 308 
MRE compared with 102/147 (69%) for US.54 The proportion of participants willing to repeat 309 
MRE was 127/147 (91%). This was lower than for US where 133/135 (99%) were happy to 310 
repeat the test.54 Overall 128/145 patients rated MRE as very or fairly acceptable, while 311 
144/146 (99%) participants rated US as very or fairly acceptable. Issues reported by patients 312 
concerning MRE mainly reflected ingesting contrast, repeated breath holds and the after-313 
effects of contrast such as diarrhoea and bloating. Perceived scan burden was significantly 314 
higher for MRE than SBUS. One important finding is that patients rated diagnostic accuracy 315 
as the most important attribute and more important than the challenges related to discomfort 316 
of undergoing scans.55 None of the included sources presented findings related to 317 
preferences of HCPs or patients as to where and when SBUS should be delivered.  318 
 319 
Discussion 320 
Mucosal healing, defined by the absence of ulcerations, is recommended as the therapeutic 321 
goal in clinical practice. MRE is the current standard for assessing SBCD, however It is 322 
expensive, time consuming and poorly tolerated by patients.7,30   323 
 324 
Meta-analyses suggest MRE and SBUS have similar accuracy for diagnosing and staging 325 
SBCD.56 SBUS could be a good alternative to more invasive and expensive imaging 326 
techniques. Besides being quick, well tolerated and readily available, SBUS is reported and 327 
interpreted at the time of scanning and allows for expedited clinical decision-making.10  328 
POCUS is reported as having impact on clinical decision making in routine IBD care by 329 
expediting clinical decision makng.10,30,36 However there is no current evidence on the impact 330 
that SBUS has on the nature of clinical decision making behaviours, or confidence of HCPs 331 
making those clinical decisions.  332 
 333 
Multiple sources referred to SBUS as inexpensive. However, none of the included sources 334 
presented clear data relating to cost or cost effectiveness of SBUS or POCUS. More data on 335 
the cost effectiveness of  SBUS are needed to encourage the implementation of SBUS in 336 
IBD services.10 SBUS involves the use of standard ultrasound equipment that is readily 337 
available in most hospitals, however increasing scanning capacity also involves increased 338 
resources such as staffing and training. SBUS is often seen as having limited clinical utility 339 
due to operator dependence.36 However, this criticism is perhaps more reflective of a 340 
previous lack of identifiable international performance and training standards.36 NHS 341 
radiology workforce is short staffed by 33%, and is already at a deficit before considering the 342 
backlog following COVID-19.57 ECCO-ESGAR Guidelines describe the dedicated training in 343 
bowel US process, and that SBUS should be performed following training in general 344 
abdominal US.8  345 
 346 
Although various SBUS activity scores are available, the methodology for development was 347 
insufficient in most studies. There are several scoring systems for disease activity 348 
assessment using SBUS in CD, however until recently none had been completely validated.  349 
 350 
There is no current work to investigate patient or HCPs preferences or service delivery. 351 
There are also questions relating to HCP perceptions of acceptability related to the 352 
diagnostic accuracy and confidence in basing clinical decisions on SBUS. It would seem 353 
prudent to investigate broader stakeholder perceptions of the use of POCUS in order to 354 
better understand perceived barriers and enablers to POCUS implementation in world-wide 355 




Scoping reviews do not formally evaluate the quality of evidence gathering information from 360 
a wide range of study designs and methods, providing a descriptive account of available 361 
information leading to broad overview of the available literature. The outcomes represent an 362 
accurate response to the research question. Continuous conversations between authors 363 
occurred throughout to ensure a unanimous decision regarding article searches, thus limiting 364 
any potential bias. The scope of background information collected, disease activity levels, 365 




SBUS has been shown have a relatively comparable accuracy to MRE in detecting presence 370 
of SBCD. SBUS, and POCUS, are used widely in central Europe, Canada and some parts of 371 
the USA, but has not been embraced in the UK and other parts of the world. The resources 372 
required in terms of equipment, are readily available in most hospitals. Resource 373 
implications for future implementation include training of gastroenterologists and staffing of 374 
supporting radiology departments 375 
 376 
Multiple sources reported SBUS as an inexpensive test, however there is scant literature to 377 
support this. Further research in this area would better inform decision makers regarding 378 
future intervention implementation. 379 
 380 
SBUS is reported as being a useful tool to expedite clinical decision making, but there is no 381 
evidence relating to the impact on the nature of clinical decision making by HCPs. Further 382 
research in this area would help us to better understand the impact of POCUS on clinical 383 
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Figures:  568 
 569 
Figure 1: Factors of Clinical utility  570 
The model of dimensions of clinical utility presented by Smart12 encompasses elements of 571 
work practice alongside other factors such as economic considerations, stakeholder 572 
acceptability and future planning for interventions and services.  Assessing the clinical utility 573 
of a new technology or technique involves asking whether the innovation is appropriate, 574 
accessible, practicable, and acceptable for the purposes of the task intended.12,58,59  575 
 576 
Figure 2: PRISMA flow diagram – Supplimental material  577 
 578 
The flow diagram depicts the flow of sources through the different phases of screening for 579 
inclusion and exclusion. we included 42 sources in our scoping review. Reasons for full test 580 
exclusion are detailed in the PRISMA flow diagram. 581 
 582 
 583 
Table 2:  Table of  included sources – supplemental material584 
 
